Chiome Bioscience Widens Cash Burn as Sales Drop and Outlook Stays Limited

Chiome Bioscience Inc. ( (JP:4583) ) just unveiled an announcement.

Chiome Bioscience reported a ninth consecutive annual loss for the fiscal year ended December 31, 2025, as net sales fell 24.0% to ¥593 million and net loss narrowed slightly to ¥982 million, with profitability metrics remaining deeply negative. Total assets and net assets declined significantly, cash and cash equivalents nearly halved, and the company maintained its no-dividend policy, while only issuing a limited 2026 forecast covering ¥600 million in sales for its Drug Discovery Support business, reflecting ongoing uncertainty in its core Drug Discovery and Development segment.

Operating cash outflows remained substantial at ¥935 million despite modest financing inflows, highlighting continued funding needs to sustain R&D and operations. The weaker balance sheet and constrained outlook underscore execution risk in advancing its drug pipeline and could heighten investor focus on Chiome’s ability to secure future partnerships or capital as it navigates a competitive biotech environment.

The most recent analyst rating on (JP:4583) stock is a Hold with a Yen116.00 price target. To see the full list of analyst forecasts on Chiome Bioscience Inc. stock, see the JP:4583 Stock Forecast page.

More about Chiome Bioscience Inc.

Chiome Bioscience Inc. is a Japan-based biotech company listed on the Tokyo Stock Exchange that operates Drug Discovery and Development and Drug Discovery Support businesses. It focuses on antibody-related technologies and services, generating revenue from contract-based research support while investing heavily in proprietary drug discovery programs.

Average Trading Volume: 578,490

Technical Sentiment Signal: Sell

Current Market Cap: Yen7.85B

For a thorough assessment of 4583 stock, go to TipRanks’ Stock Analysis page.